Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

NEXT STORY
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management
PREV STORY
Tissue Sealants and Adhesives (Wound Care Management) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021

author_avatar
NASDAQ Market News

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

author_avatar
NASDAQ Market News

Independence Blue Cross Foundation awards nearly $1.8 million in grants

PHILADELPHIA, PA., Sept. 16, 2015 (GLOBE NEWSWIRE) -- The Independence Blue Cross Foundation (Foundation) ...

author_avatar
NASDAQ Market News